Quarterly Results Took Shares Of MetLife (MET), Cigna (CI) High, And Merck’s (MRK) Low

MetLife, Inc. (MET) was up +5.12% to $51.9. For the fourth fiscal quarter, the U.S. insurer posted a better-than-expected rise in adjusted earnings, with investment growth and underwriting in some of its U.S. companies. The quarter’s adjusted earnings per share are $2.03, compared to $1.53 and $1.98 a year ago. The income was 20.6 billion dollars, up from 18.2 billion dollars a year ago.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Cigna Corporation (CI) was down -6.4% to $205.38. A lower-than-expected profit for the quarter ended was posted by Connecticut’s U.S. insurer, which also reported better-than-expected sales for the time. Compared to $977 million a year ago, quarterly net income was $4.14 billion, or $11.45 a share. For the year, the company generated $160.4 billion in sales, $8.5 billion in net revenue, and $22.96 per share of earnings. Net income was $6.8 billion in 2020 and $18.45 per share. In 2021, it is projected to be at least $6.95 billion, or $20 per share, with at least $165 billion in sales.

Merck & Co., Inc. (MRK) was down -1.67% to $76.03 for releasing lower-than-expected fourth-quarter results and also confirmed the resignation of Ken Frazier, its chief executive, planned for June. There was $12.5 billion in quarterly revenue, up 5 percent. With acquisition costs and impairments, the GAAP cost per share was 83 cents. Earnings per share adjusted are $1.32. For $12.7 billion in sales, the consensus was $1.38 adjusted EPS. The U.S. biotechnology firm anticipates revenue of between $51.8 billion and $53.8 billion for fiscal 2021, a GAAP EPS of between $5.52 and $5.72, and an adjusted EPS of between $6.48 and $6.68.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free